Seizure-free Days Observed in Randomized Placebo-controlled Add-on Trials with Levetiracetam in Partial Epilepsy

Ilo E Leppik, Martha Morrell, Philippe Godfroid, Celestina Arrigo

Research output: Contribution to journalReview article

22 Scopus citations

Abstract

Purpose: We examined the effect of adjunctive levetiracetam (LEV; 1,000 to 3,000 mg/day) on the number of seizure-free days gained per quarter in adult patients with refractory partial-onset epilepsy. Methods: The treatment effect was studied in a meta-analysis using individual patient data of a subpopulation of patients (n = 846) emerging from the three randomized, double-blind, placebo-controlled, phase III trials (n = 904). Results: Adding LEV effectively increased the number of days without seizures by 5.19 days per quarter [95% confidence interval (CI), 3.63-6.76; p = 0.0001; titration and stable dose periods]. Conclusions: LEV adjunctive treatment shows a clear benefit in terms of seizure-free days gained for patients with refractory epilepsy. This gain is significant for the pooled and for each LEV dose compared with placebo.

Original languageEnglish (US)
Pages (from-to)1350-1352
Number of pages3
JournalEpilepsia
Volume44
Issue number10
DOIs
StatePublished - Oct 1 2003

Keywords

  • Effectiveness
  • Epilepsy
  • Levetiracetam
  • Seizure-free days

Fingerprint Dive into the research topics of 'Seizure-free Days Observed in Randomized Placebo-controlled Add-on Trials with Levetiracetam in Partial Epilepsy'. Together they form a unique fingerprint.

  • Cite this